Rita daniels twitter1/23/2024 ![]() ![]() However, as Phil Cyr from Precision Value & Health pointed out, the conversation is shifting towards the overall budget impact and affordability, especially as therapies for more common diseases are developed. Here are some insights worth noting:ġ️⃣ The Evolving Landscape of Gene Therapy Costs:ĭespite high prices like BioMarin Pharmaceutical Inc.'s Roctavian at $2.9m and uniQure/CSL's Hemgenix at $3.5m, these therapies have been seen as cost-effective for treating rare diseases. ![]() New Analysis by Tufts’ NEWDIGS Shows that Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates than Other Treatments - Alliance for Regenerative MedicineĪRM's annual Meeting on the Mesa #CGMesa23 concluded recently, offering a rich platform for discussions among key players in life sciences, venture capital, biopharma, service providers and consultants. Want some deeper insights? Make your way to the Aseptic Technologies Ballroom at 10:45am PT for our spotlight session with Mark Trusheim, Strategic Director of NEWDIGS. ➡ Gene therapies are twice as likely to gain FDA approval when they enter Phase 1 compared to the average drug in similar therapeutic areas. ➡ Once entering Phase 1, rare disease durable gene therapies are two to three-and-a-half times more likely to gain FDA approval compared to the average drug in clinical trials. ➡ CAR-T/TCR therapies for blood cancers are three times as likely to gain approval from the FDA when entering Phase 1 compared to the average oncology drug. Here are a few highlights from the findings: We have new data that show #cellandgenetherapy is redefining what clinical success looks like.Īt #CGMesa23, the NEWDIGS Initiative at Tufts Medical Center released new analysis showing that durable cell and gene therapies have clinical success rates between two and three times higher than other types of treatments. It’s conventional wisdom that the clinical trial journey is notoriously difficult, with high rates of failure. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |